Survodutide

A dual GLP-1 and glucagon receptor agonist studied for obesity and non-alcoholic steatohepatitis. An alternative to tirzepatide with a different receptor profile emphasising liver health.

Combines GLP-1 receptor appetite suppression and insulin secretion with glucagon receptor activation that raises energy expenditure and drives hepatic fat oxidation.

Survodutide pairs the appetite signal of GLP-1 with glucagon activity that pushes the liver to burn stored fat. That combination is why much of its research focus sits on fatty liver disease alongside weight.

• Percentage body weight reduction
• Hepatic fat fraction
• Liver fibrosis staging
• Energy expenditure
• Glycaemic markers

• Obesity Phase 2 weight endpoints
• Non-alcoholic steatohepatitis resolution
• Liver fibrosis improvement
• Glycaemic control
• Energy expenditure

Developed jointly by Boehringer Ingelheim and Zealand Pharma as a dual GLP-1/glucagon agonist aimed at both obesity and metabolic liver disease.

Men and women 35-65 focused on advanced fat loss, liver health and NASH research.

• Reconstitute with sterile or bacteriostatic water.
• Add diluent slowly down the vial wall.
• Extended half-life supports weekly protocol modelling.
• Store lyophilised at -20C, reconstituted at 2-8C.
• Protect from light.

• Glucagon receptor activity distinguishes it from GIP-based duals.
• Liver endpoints are a primary research focus.
• Dose escalation drives tolerability in trial data.
• Phase 3 data still emerging.